Given that ErbB contributes to IGF-IR/InsR and ER antagonist resistance, co-targeting ErbB, IGF-IR/InsR, and ER may achieve maximal anti-cancer effect on ER+ breast cancer [110]. This evidence concerns the gene ESR1 and cancer.